Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Adherex Technologies Inc, under license from McGill University, is developing ADH-1, an intravenous N-cadherin antagonist that specifically disrupts the disorganized interactions between N-cadherin molecules in tumor blood vessels, as a potential anticancer compound. By May 2005, ADH-1 was in phase Ib/II clinical trials in Europe and the US, and phase II clinical trials in Canada.